Positive results prompt AstraZeneca to end Crestor trial

03/31/2008 | Wall Street Journal (free content), The · USA Today

AstraZeneca on Monday announced it will halt a trial of Crestor earlier than scheduled after results showed the cholesterol-lowering drug had significant advantages over placebo. The study found Crestor effective in lowering the risk of major cardiovascular events in patients with high levels of C-reactive protein, which has been associated with heart problems.

View Full Article in:

Wall Street Journal (free content), The · USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX